文献速递白血病造血干细胞移植与细胞治疗

干性筛选揭示C3orf54/INKA1促进人白血病干细胞潜伏

A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency.
PubMed 文献 · Blood · 2019-02-22

研究将功能验证的白血病干细胞(LSC)特异性基因与已知蛋白互作因子结合,筛选64个候选基因,在脐血造血干/祖细胞中进行体内竞争性功能获得筛选。最强候选孤儿基因C3orf54/INKA1过表达使患者来源AML模型(8227)的LSC滞留于原始状态,早期再增殖延迟但后期自我更新LSC扩增;INKA1沉默则降低再生潜能。机制上INKA1通过干扰靶蛋白PAK4核定位调控G0退出,并伴随全局H4K16ac水平降低。

要点

  • 在脐血造血干/祖细胞体内竞争性筛选64个候选基因,鉴定出C3orf54/INKA1。
  • INKA1过表达使患者来源AML模型(8227)的LSC滞留于原始状态并延迟早期再增殖。
  • INKA1沉默降低原代AML的再生潜能。

核心结论

  • INKA1是LSC潜伏的新型调控因子,并揭示再生过程中干细胞动力学调控与干细胞库大小之间的联系。

研究设计与样本

  • 研究将功能验证的LSC特异性基因数据与其已知蛋白互作因子结合,选择64个候选基因。
  • 在脐血造血干/祖细胞中进行体内竞争性功能获得筛选,以鉴定增强干性的基因。

主要发现

  • 筛选排名靠前的命中基因一致表现为限制早期再增殖动力学同时保留再生潜能。
  • 在患者来源AML模型(8227)中过表达C3orf54/INKA1,促进LSC滞留于原始状态,表现为CD34+细胞相对扩增、细胞在G0期积累以及分化后代输出减少。
  • 尽管早期再增殖延迟,INKA1过表达在后期导致自我更新LSC扩增。
  • 在原代AML中沉默INKA1降低再生潜能。
  • 多维共聚焦分析发现INKA1通过干扰其靶蛋白PAK4的核定位来调控G0退出,并伴随全局H4K16ac水平降低。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a growing body of evidence that the molecular properties of leukemia stem cells (LSCs) are associated with clinical outcomes in acute myeloid leukemia (AML), and LSCs have been linked to therapy failure and relapse. Thus, a better understanding of the molecular mechanisms that contribute to the persistence and regenerative potential of LSCs is expected to result in the development of more effective therapies. We therefore interrogated functionally validated data sets of LSC-specific genes together with their known protein interactors and selected 64 candidates for a competitive in vivo gain-of-function screen to identify genes that enhanced stemness in human cord blood hematopoietic stem and progenitor cells. A consistent effect observed for the top hits was the ability to restrain early repopulation kinetics while preserving regenerative potential. Overexpression (OE) of the most promising candidate, the orphan gene C3orf54/INKA1, in a patient-derived AML model (8227) promoted the retention of LSCs in a primitive state manifested by relative expansion of CD34+ cells, accumulation of cells in G0, and reduced output of differentiated progeny. Despite delayed early repopulation, at later times, INKA1-OE resulted in the expansion of self-renewing LSCs. In contrast, INKA1 silencing in primary AML reduced regenerative potential. Mechanistically, our multidimensional confocal analysis found that INKA1 regulates G0 exit by interfering with nuclear localization of its target PAK4, with concomitant reduction of global H4K16ac levels. These data identify INKA1 as a novel regulator of LSC latency and reveal a link between the regulation of stem cell kinetics and pool size during regeneration.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kaufmann KB, Garcia-Prat L, Liu Q, et al. A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency. Blood. 2019. PMID: 30796022. doi:10.1182/blood-2018-10-881441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。